scholarly journals Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care

Lab on a Chip ◽  
2011 ◽  
Vol 11 (20) ◽  
pp. 3411 ◽  
Author(s):  
ShuQi. Wang ◽  
Xiaohu Zhao ◽  
Imran Khimji ◽  
Ragip Akbas ◽  
Weiliang Qiu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Phone ◽  
Point Of Care

Remote Mentoring of Point-of-Care Ultrasound Skills to Inexperienced Operators Using Multiple Telemedicine Platforms: Is a Cell Phone Good Enough?

2018 ◽  
Vol 37 (11) ◽  
pp. 2517-2525 ◽  
Author(s):  
Andrew Smith ◽  
Reuben Addison ◽  
Peter Rogers ◽  
Jordan Stone-McLean ◽  
Sarah Boyd ◽  
...  
Keyword(s):  
Cell Phone ◽  
Point Of Care ◽  
Point Of Care Ultrasound ◽  
A Cell

scholarly journals CA125 and Ovarian Cancer: A Comprehensive Review

Cancers ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3730
Author(s):  
Parsa Charkhchi ◽  
Cezary Cybulski ◽  
Jacek Gronwald ◽  
Fabian Oliver Wong ◽  
Steven A. Narod ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Point Of Care ◽  
Prognostic Indicator ◽  
Type I ◽  
Average Risk ◽  
Type Ii ◽  
Gynecological Malignancy ◽  
Primary Ovarian Cancer ◽  
Low Volume

Ovarian cancer is the second most lethal gynecological malignancy. The tumour biomarker CA125 has been used as the primary ovarian cancer marker for the past four decades. The focus on diagnosing ovarian cancer in stages I and II using CA125 as a diagnostic biomarker has not improved patients’ survival. Therefore, screening average-risk asymptomatic women with CA125 is not recommended by any professional society. The dualistic model of ovarian cancer carcinogenesis suggests that type II tumours are responsible for the majority of ovarian cancer mortality. However, type II tumours are rarely diagnosed in stages I and II. The recent shift of focus to the diagnosis of low volume type II ovarian cancer in its early stages of evolution provides a new and valuable target for screening. Type II ovarian cancers are usually diagnosed in advanced stages and have significantly higher CA125 levels than type I tumours. The detection of low volume type II carcinomas in stage IIIa/b is associated with a higher likelihood for optimal cytoreduction, the most robust prognostic indicator for ovarian cancer patients. The diagnosis of type II ovarian cancer in the early substages of stage III with CA125 may be possible using a higher cutoff point rather than the traditionally used 35 U/mL through the use of point-of-care CA125 assays in primary care facilities. Rapid point-of-care testing also has the potential for effective longitudinal screening and quick monitoring of ovarian cancer patients during and after treatment. This review covers the role of CA125 in the diagnosis and management of ovarian cancer and explores novel and more effective screening strategies with CA125.

scholarly journals A Cell-Phone-Based Acoustofluidic Platform for Quantitative Point-of-Care Testing

ACS Nano ◽  
2020 ◽  
Vol 14 (3) ◽  
pp. 3159-3169 ◽  
Author(s):  
Liying Zhang ◽  
Zhenhua Tian ◽  
Hunter Bachman ◽  
Peiran Zhang ◽  
Tony Jun Huang
Keyword(s):  
Cell Phone ◽  
Point Of Care ◽  
Point Of Care Testing ◽  
A Cell

scholarly journals Point-of-care Ratiometric Fluorescence Imaging of Tissue for the Diagnosis of Ovarian Cancer

Theranostics ◽  
2019 ◽  
Vol 9 (16) ◽  
pp. 4597-4607 ◽  
Author(s):  
Xiaobo Zhou ◽  
Yawei Liu ◽  
Qiyu Liu ◽  
Luzhe Yan ◽  
Meng Xue ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Fluorescence Imaging ◽  
Point Of Care ◽  
Ratiometric Fluorescence

scholarly journals Loop-Mediated Isothermal Amplification in Core-Shell Beads Assay for the Detection of Tyrosine Kinase AXL Over Expression

2021 ◽  
Author(s):  
Kamalalayam Rajan Sreejith ◽  
Muhammad Umer ◽  
Pradip Singha ◽  
Nhat-Khuong Nguyen ◽  
Surasak Kasetsirikul ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Diagnostic Method ◽  
Prognostic Biomarker ◽  
Point Of Care ◽  
Isothermal Amplification ◽  
Core Shell ◽  
Over Expression ◽  
Loop Mediated Isothermal Amplification ◽  
Ovarian Cancers ◽  
Shell Beads

The upregulated expression of thyrosine kinase AXL has been reported in several hematologic and solid human tumors including gastric, breast, colorectal, prostate, and ovarian cancers. Thus, AXL can potentially serve as a diagnostic and prognostic biomarker for various cancers. This paper reports the first-ever use of loop-mediated isothermal amplification (LAMP) of the AXL gene as a diagnostic method for ovarian cancer. We demonstrated simple instrumentation toward a point-of-care device to perform LAMP. This paper also reports the first-ever use of core-shell beads as a microreactor to perform LAMP as an attempt to promote environmentally friendly laboratory practices.

scholarly journals Correction to A Cell-Phone-Based Acoustofluidic Platform for Quantitative Point-of-Care Testing

ACS Nano ◽  
2020 ◽  
Vol 14 (8) ◽  
pp. 10747-10747
Author(s):  
Liying Zhang ◽  
Zhenhua Tian ◽  
Hunter Bachman ◽  
Peiran Zhang ◽  
Tony Jun Huang
Keyword(s):  
Cell Phone ◽  
Point Of Care ◽  
Point Of Care Testing ◽  
A Cell

scholarly journals A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care

2014 ◽  
Vol 8 (1) ◽  
pp. 37-48 ◽  
Author(s):  
Basil H. Shadfan ◽  
Archana R. Simmons ◽  
Glennon W. Simmons ◽  
Andy Ho ◽  
Jorge Wong ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Detection ◽  
Point Of Care ◽  
Microfluidic Platform ◽  
Biomarker Panel ◽  
Early Ovarian Cancer

scholarly journals SERS-based detection of haptoglobin in ovarian cyst fluid as a point-of-care diagnostic assay for epithelial ovarian cancer

2019 ◽  
Vol Volume 11 ◽  
pp. 1115-1124 ◽  
Author(s):  
Jayakumar Perumal ◽  
Aniza Mahyuddin ◽  
Ghayathri Balasundaram ◽  
Douglas Goh ◽  
Chit Yaw Fu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Ovarian Cyst ◽  
Point Of Care ◽  
Cyst Fluid ◽  
Diagnostic Assay ◽  
Ovarian Cyst Fluid
Sign in / Sign up

Export Citation Format

Share Document